2018
Racial/ethnic differences in the prognostic utility of left ventricular mass index for incident cardiovascular disease
Akintoye E, Mahmoud K, Shokr M, Sandio A, Mallikethi‐Reddy S, Sheikh M, Adegbala O, Egbe A, Briasoulis A, Afonso L. Racial/ethnic differences in the prognostic utility of left ventricular mass index for incident cardiovascular disease. Clinical Cardiology 2018, 41: 502-509. PMID: 29663526, PMCID: PMC6490106, DOI: 10.1002/clc.22914.Peer-Reviewed Original ResearchMeSH KeywordsAgedAsianBlack or African AmericanCardiovascular DiseasesComorbidityDatabases, FactualDisease ProgressionFemaleHispanic or LatinoHumansHypertrophy, Left VentricularIncidenceMagnetic Resonance Imaging, CineMaleMiddle AgedPredictive Value of TestsPrognosisProportional Hazards ModelsRacial GroupsRisk FactorsTime FactorsUnited StatesVentricular Function, LeftVentricular RemodelingWhite PeopleConceptsLeft ventricular mass indexLeft ventricular hypertrophyNon-Hispanic whitesVentricular mass indexCVD eventsIncident CVDMass indexPrognostic utilityEthnic differencesFuture cardiovascular disease eventsOptimal cutpointCardiovascular disease eventsFuture CVD eventsIncident cardiovascular diseaseRisk stratification strategiesIncident cardiovascular outcomesMulti-Ethnic StudyRace/ethnicityCardiovascular outcomesLVMI valuesVentricular hypertrophyCardiovascular diseaseDisease eventsCox modelStratification strategies
2016
Novel biomarkers with potential for cardiovascular risk reclassification
Mallikethi-Reddy S, Briasoulis A, Akintoye E, Afonso L. Novel biomarkers with potential for cardiovascular risk reclassification. Biomarkers 2016, 22: 189-199. PMID: 27299923, DOI: 10.1080/1354750x.2016.1201540.Peer-Reviewed Original ResearchConceptsRed cell distribution widthCardiovascular risk reclassificationRisk reclassificationNovel risk markersCardiovascular risk predictionCell distribution widthCardiovascular riskCVD eventsMultivariate risk modelIntermediate riskAbsolute riskAsymptomatic individualsSerum biomarkersRisk markersTreatment recommendationsRisk factorsCystatin CNovel biomarkersRisk modelDistribution widthBiomarkersRisk predictionPatientsRiskReclassification